B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
KYNB
Kyntra BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A favorable FG-3246 interim analysis, roxadustat trial initiation and a successful listing appeal could improve the outlook. The August company release reported $95.7 million of cash, investments and accounts receivable at June 30 and expected that combined balance to fund operating plans into 2028 [#SEC-8K-2026-08-13].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
FG-3246 interim efficacy and safety results may disappoint or be delayed [#SEC-8K-2026-08-13].
Momentum
95
Value
59
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $8.50 · Bear $1.50Analysis 2026-10-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $36.80
Why
Momentum95 · Δ7d -
Value59 · Δ7d -0.2
Sentiment55 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • FG-3246 interim efficacy and safety results may disappoint or be delayed [#SEC-8K-2026-08-13].
- • Nasdaq delisting remains possible despite the hearing stay; no favorable panel outcome is assured [#8-K-2026-10-06].
- • An adverse listing-panel decision or disappointing clinical data could overwhelm pipeline optionality.
Catalyst clock
2026-12-31
FG-3246 Phase 2 interim analysis
Lead driver: Value · See fundamentals
Momentum
95
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.7
Sentiment
55
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 94.6 / Value 59.4 / Sentiment 54.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$18.22M
Beta
0.84
Shares Out
4.05M
P/E (TTM)
0.2
P/S (TTM)
4.35
P/FCF (TTM) · Derived
-0.48
Rev YoY
-209.3%
EPS YoY
-257.3%
Gross Margin
+1.6%
Op Margin
-596.1%
Net Debt
-$69.42M
Current Ratio
2.69
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data